Hologic completed the acquisition of Mobidiag from Autobio Diagnostics and Springvest for $795m.

Hologic, a women's health company, completed the acquisition of Mobidiag, a biotechnology company, from Autobio Diagnostics, a clinical diagnostics company, and Springvest, an investment company, for $795m. “Acquiring Mobidiag will further strengthen our international and diagnostics businesses by enabling us to expand into the large, fast-growing acute care adjacency with a near-patient testing solution that offers ease of use, multiplex capability and rapid turnaround time. We believe that Mobidiag has developed a differentiated platform that addresses many of the historical challenges of multiplexed point-of-care molecular testing," Jan Verstreken, Hologic President.